

Technology/ Title	Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine	
Technology Type	<input type="checkbox"/> Biotechnology	<input type="checkbox"/> Device/Diagnostics
	<input checked="" type="checkbox"/> Pharmaceutical	<input type="checkbox"/> Others: _____ -
Contact Person	Name: Hua-Hsuan Liang	Title: Acting Section Chief
	Telephone(work): 886-37-206166#33206	Mobile:
	Email: huahsuan@nhri.edu.tw	
Link	http://	
Technology Description	The present invention relates to a method for decreasing the psychotomimetic side effects and addictive disorders of ketamine by using betaine or a betaine metabolite. Especially, the present invention relates to a method for depression treatment comprising administrating ketamine combined with betaine or a betaine metabolite N,N dimethylglycine ( DMG ).	
Intellectual Property	Taiwan, Japan, USA, Canada	
Key Publications	<ol style="list-style-type: none"> <li>1. Lin J, Chan MH, Lee MY, Chen YC, <b>Chen HH</b>. 2016. N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. Prog Neuropsychopharmacol Biol Psychiatry. 71(3):7-13</li> <li>2. Lin J, Chan MH, Lee MY, Chen YC, <b>Chen HH</b>. 2016. Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice. Psychopharmacology 233(17):3223-35</li> <li>3. Chen ST, Hsieh CP, Lee MY, Chen LC, Huang CM, <b>Chen HH</b>, Chan MH 2021 Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice. Biomedicine &amp; Pharmacotherapy 144, 112369</li> </ol>	
Business Opportunity	The global market for antidepressants was worth USD 18.52 billion in 2022 and would reach USD 30.73 billion by 2030. Ketamine is a fast-acting antidepressant. Esketamine has been proved by FDA for treatment-resistant depression. Concerns still exist over adverse clinical outcomes that may stem from indefinite ketamine exposure, including cognitive impairment, increased propensity for delusions, and abuse liability. The present invention further provides a method capable of alleviating concerns for ketamine use.	